MK-0752 is primarily used in research and clinical studies focused on cancer treatment, particularly targeting cancers that are driven by abnormal Notch signaling pathways. It functions as a gamma-secretase inhibitor, which helps in blocking the activation of Notch receptors, a process often implicated in the growth and survival of cancer cells. This makes it a potential therapeutic agent for various types of cancers, including breast cancer, leukemia, and brain tumors. Additionally, MK-0752 is being explored for its efficacy in combination therapies, where it is used alongside other anticancer drugs to enhance treatment outcomes. Its role in inhibiting Notch signaling also opens avenues for studying its impact on other diseases where Notch pathways are dysregulated.